Scientists assessed the effects of the hosphoinositide 3-kinase δ inhibitor AMG319 in human patients with head and neck cancer in a neoadjuvant, double-blind, placebo-controlled randomized Phase II trial.
[Nature]
Home Newsletters Human Immunology News Intermittent PI3Kδ Inhibition Sustains Anti-Tumor Immunity and Curbs irAEs
